rhNGF

DRUG2 trials

Sponsors

Dompé Farmaceutici S.p.A

Conditions

GlaucomaOcular Discomfort

Phase 1

Study to Evaluate Safety and Efficacy of rhNGF Eye Drops Solution Versus Vehicle in Patients With Glaucoma

CompletedNCT02855450

Dompé Farmaceutici S.p.AGlaucoma

Start: 2016-12-31End: 2018-05-31Updated: 2020-11-25

Phase 2

A 8 Weeks Study to Evaluate Efficacy & Safety of rhNGF vs Vehicle in Patients After Cataract and Refractive Surgery

CompletedNCT03035864

Dompé Farmaceutici S.p.AOcular Discomfort

Start: 2017-01-12End: 2017-09-04Updated: 2024-04-19

Related Papers

Phase 1b Randomized Controlled Study of Short Course Topical Recombinant Human Nerve Growth Factor (rhNGF) for Neuroenhancement in Glaucoma: Safety, Tolerability, and Efficacy Measure Outcomes.

2021-11-1326 citations

Effect of recombinant human nerve growth factor eye drops in patients with dry eye: a phase IIa, open label, multiple-dose study

British Journal of Ophthalmology2019-04-0364 citations